{
  "actions": [
    {
      "action_type": "treatment",
      "evidence_level": "CLINICAL_TRIAL",
      "evidence_tier": "TIER_2",
      "payload": {
        "drug": "olaparib",
        "drug_class": "parp_inhibitor",
        "priority": 1,
        "requires": null,
        "source_gene": "NF1"
      },
      "rationale": "PARP maintenance may overcome MAPK-mediated resistance",
      "title": "Consider alternative: olaparib"
    },
    {
      "action_type": "treatment",
      "evidence_level": "CLINICAL_TRIAL",
      "evidence_tier": "TIER_2",
      "payload": {
        "drug": "trametinib",
        "drug_class": "mek_inhibitor",
        "priority": 2,
        "requires": null,
        "source_gene": "NF1"
      },
      "rationale": "Direct MAPK pathway inhibition for NF1 loss",
      "title": "Consider alternative: trametinib"
    },
    {
      "action_type": "treatment",
      "evidence_level": "STANDARD_OF_CARE",
      "evidence_tier": "TIER_1",
      "payload": {
        "drug": "bevacizumab",
        "drug_class": "vegf_inhibitor",
        "priority": 2,
        "requires": null,
        "source_gene": "NF1"
      },
      "rationale": "Add anti-VEGF to platinum backbone",
      "title": "Consider alternative: bevacizumab"
    },
    {
      "action_type": "treatment",
      "evidence_level": "VALIDATED",
      "evidence_tier": "TIER_3",
      "payload": {
        "from_regimen": "carboplatin/paclitaxel",
        "to_regimen": "carboplatin/paclitaxel + bevacizumab"
      },
      "rationale": "Add bevacizumab for high-risk disease",
      "title": "Regimen change: carboplatin/paclitaxel \u2192 carboplatin/paclitaxel + bevacizumab"
    },
    {
      "action_type": "monitoring",
      "evidence_level": null,
      "evidence_tier": null,
      "payload": {
        "biomarker_frequency": "CA-125 every 2 weeks",
        "bone_marrow_frequency": null,
        "ctdna_targets": null,
        "imaging_frequency": "CT every 2-3 months",
        "mrd_frequency": null
      },
      "rationale": "Playbook monitoring adjustments",
      "title": "Adjust monitoring"
    },
    {
      "action_type": "handoff",
      "evidence_level": null,
      "evidence_tier": null,
      "payload": {
        "action": "rerank_drugs",
        "agent": "drug_efficacy",
        "payload": {
          "avoid_classes": [],
          "prefer_alternatives": [
            {
              "class": "parp_inhibitor",
              "drug": "olaparib",
              "priority": 1
            },
            {
              "class": "mek_inhibitor",
              "drug": "trametinib",
              "priority": 2
            },
            {
              "class": "vegf_inhibitor",
              "drug": "bevacizumab",
              "priority": 2
            }
          ],
          "resistance_context": {
            "detected_genes": [
              "NF1"
            ],
            "disease": "ovarian"
          }
        }
      },
      "rationale": "Handoff to drug_efficacy",
      "title": "Downstream handoff: drug_efficacy"
    },
    {
      "action_type": "handoff",
      "evidence_level": null,
      "evidence_tier": null,
      "payload": {
        "action": "update_regimen",
        "agent": "care_plan",
        "payload": {
          "current_regimen": null,
          "recommended_regimens": [
            {
              "from": "carboplatin/paclitaxel",
              "rationale": "Add bevacizumab for high-risk disease",
              "to": "carboplatin/paclitaxel + bevacizumab"
            }
          ],
          "resistance_rationale": "Resistance detected: NF1"
        }
      },
      "rationale": "Handoff to care_plan",
      "title": "Downstream handoff: care_plan"
    },
    {
      "action_type": "handoff",
      "evidence_level": null,
      "evidence_tier": null,
      "payload": {
        "action": "intensify_monitoring",
        "agent": "monitoring",
        "payload": {
          "biomarker_frequency": "CA-125 every 2 weeks",
          "bone_marrow_frequency": null,
          "ctdna_targets": null,
          "escalation_triggers": [
            "New lesions on imaging",
            "CA-125 rise >50% from nadir"
          ],
          "imaging_frequency": "CT every 2-3 months",
          "mrd_frequency": null
        }
      },
      "rationale": "Handoff to monitoring",
      "title": "Downstream handoff: monitoring"
    }
  ],
  "confidence": null,
  "endpoint": "/api/care/resistance_playbook_v2",
  "mechanisms": [
    {
      "biomarkers": [
        "NF1"
      ],
      "detected": true,
      "evidence_level": null,
      "evidence_tier": "TIER_4",
      "mechanism": "mutation_panel",
      "rationale": "Detected genes from tumor_context: NF1",
      "source": "tumor_context.somatic_mutations"
    }
  ],
  "probability": null,
  "provenance": {
    "code_version": "unknown",
    "contract_version": "resistance_contract_v1",
    "disease": "ovarian_cancer_hgs",
    "disease_normalized": "ovarian_cancer_hgs",
    "disease_original": "ovarian_cancer_hgs",
    "flags": [
      "MISSING_CA125_HISTORY",
      "INPUT_LEVEL_L1"
    ],
    "generated_at": "2025-12-26T10:53:08.960673",
    "inputs_snapshot_hash": "d6066cd98e6d33c9702b679efd3912047b9fccc2cce84c1c4b47dc4414a414b5",
    "playbook_disease": "ovarian",
    "playbook_provenance": {
      "alternatives_count": 3,
      "cross_resistance_detected": null,
      "cytogenetics": null,
      "detected_resistance": [
        "NF1"
      ],
      "disease": "ovarian",
      "line_multiplier_applied": 1.0,
      "playbook_source": "OV_RESISTANCE_PLAYBOOK",
      "prior_therapies": null,
      "regimen_changes_count": 1,
      "service_version": "resistance_playbook_v1.0_dry",
      "treatment_line": 1
    },
    "run_id": "7a4f40f5c0243ba7",
    "service_version": "resistance_playbook_v1.0_dry"
  },
  "receipts": [],
  "risk_level": null,
  "warnings": [
    "MISSING_CA125_HISTORY",
    "INPUT_LEVEL_L1"
  ]
}